Key clinical point: The investigational, once-daily oral Janus kinase 1 inhibitor abrocitinib met all primary and secondary endpoints in a pivotal phase 3 trial.
Major finding: An Eczema Area and Severity Index–75 response rate was achieved at week 12 in 63% of atopic patients on oral abrocitinib monotherapy at 200 mg once daily, 40% on 100 mg, and 12% on placebo, with a statistically significant separation from placebo by week 2 for both doses.
Study details: This was a pivotal phase 3, double-blind, randomized trial including 387 adolescents and adults with moderate or severe atopic dermatitis.
Disclosures: The presenter reported receiving research grants from and serving as a consultant to Pfizer, the study sponsor, as well as having financial relationships with roughly a dozen other pharmaceutical companies.
Simpson E. EADV late breaker.